Mobile

A randomised, open -label, parallel-group, international, multicenter phase III study of oral ZD1839 (IRESSA) versus intravenous docetaxel (Taxotere) in patients with locally advanced or metastatic re...

Update Il y a 4 ans
Reference: EUCTR2004-002943-28

A randomised, open -label, parallel-group, international, multicenter phase III study of oral ZD1839 (IRESSA) versus intravenous docetaxel (Taxotere) in patients with locally advanced or metastatic recurrent non small cell lung cancer who have previously received platinum based chemotherapy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare overall survival between ZD1839 and docetaxel

Inclusion criteria

  • Locally advanced of metastatic recurrent non-small cell lung cancer

Links